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Objectives: Acute lymphoblastic leukemia (ALL) is an aggressive cancer especially in adults as only 20–40%
are cured with current treatment regimens.
Design and methods:We measured survivin and tumor necrosis factor-alpha (TNF-α) in serum of 30 ALL
patients before and after induction therapy and compared to 30 age and sex matched normal adults.
Results: Survivin at cutoff value 15.18 pg/mL was detected in all ALL patients before therapy but in only
83.33% after therapy and not detected in the control group; Pb0.001. However TNF-α at cutoff value 60.05 pg/
mL was detected in 90% ALL patients before therapy and 86.6% after therapy that was signiﬁcantly higher than
the control group (20%); Pb0.001. Survivin showed a signiﬁcant positive correlation with TNF-α (Pb0.05),
bone marrow blast cells (Pb0.01), peripheral blast cells (Pb0.05) and Philadelphia chromosome (Pb0.01).
Conclusions: Survivin may have an important role in the development of acute leukemia and it could serve
as a signiﬁcant prognostic marker.
2011 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Acute lymphoblastic leukemia (ALL) and chronic lymphocytic
leukemia (CLL) are the most common types of leukemia in children
and in adults, respectively. Some ALL patients suffer from refractory or
recurrent disease and cannot be cured with conventional chemothera-
py [1]. Treatment of acute lymphoblastic leukemia in adults presents a
formidable challenge. While overall results have improved over the
past 3 decades the long-term 10 year survival for patients aged less
than 60 years is only in the range of 30–40% [2].
Tumor necrosis factor α (TNF-α) has a direct cytotoxic effect on
various tumor cells. The most noticeable character of anti-tumor is
speciﬁcally killing tumor cells in vivo and in vitro without toxic action
on normal cells [3]. TNF-α is considered the most effective antitumor
cytokine, it was found that its main mechanism is inducing apoptosis
of tumor cells [4].
On the other hand survivin, a unique member of the inhibitor of
apoptosis protein (IAP) family; plays an important role in regulating
both apoptosis and cell division [5]. Overexpression of survivin is asso-
ciated with increased risk of recurrence and poor outcome in a variety
of cancers [6] including hematologic malignancies [7]. Expression of
survivin is up to ten-fold higher in ALL blasts than in normal peripheral
blood and bone marrow. The efﬁcacy of survivin-speciﬁc cytotoxic Tistry, Faculty of Medicine, Ain
859928.
med).
mists. Published by Elsevier Inc. Opcells has already been shown for both ALL as well as CLL [8]. In cancer
patients, the fact that survivin overexpression may provide a survival
beneﬁt for tumor cells and that its enhanced expression is almost
completely restricted to malignant tissues makes survivin an interest-
ing target for the development of immunotherapeutic strategies [9].
Rödel et.al. [10] reported that survivin is an antiapoptotic gene which
is overexpressed in most human tumors and involved in mitotic check-
point control. High levels of survivin expression have been associated
with cancer progression, drug resistance, poor prognosis, and short
patient survival. Interestingly Schmidt et al. [9] found that survivin
expression can be up-regulated in activated B and T lymphocytes on
stimulation with tumor necrosis factor α (TNF-α).
So far, there was no report about the relation of survivin protein in
response to the therapy in acute lymphoblastic adult patients with
poor survival outcome. The current study was therefore performed to
determine survivin in serum and other apoptotic factor as TNF-α espe-
cially in adult ALL and asses their prognostic relevance.
Patients and methods
This study included 30 subjects selected from those treated at the
Clinical Hematology Unit in Ain Shams University hospital in the period
from 2008 to 2009 and 30 apparently healthy normal volunteers
matching the patients for age and sex. Leukemia was diagnosed and
classiﬁed according to the criteria of the French-American-British
(FAB) Cooperative Group [11]. The subjects were divided into 3 groups:
Control Group (Group A) included 30 normal adults (22 males anden access under CC BY-NC-ND license.
Fig. 1. Serum survivin level in ALL patients before and after therapy and control groups.
Fig. 2. Serum TNF-α level in ALL patients before and after therapy and control groups.
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patients (21 males and 9 females) with mean 37.9±14.3 years; they
were further divided into: patients before receiving any treatment
(groupB) and follow-up patients after therapy (group C). They included
19 patients diagnosed as having pre B-ALL (2 with +ve Philadelphia
chromosome), 2 patients as having B-ALL and 9 patients as having
T-ALL (3 with+ve Philadelphia chromosome). The median percentage
of leukemic blasts in the bone marrow and blood samples was 87%
(range 50–97%). All bone marrow samples and the majority of periph-
eral blood samples contained more than 70% blast (range from 50 to
80%). The patients were treated with standard induction therapy of
ALL [Adriamycin 25mg/m2 and vincristin 1.4mg/m2 days 1,8,15 and
22 together with L-Asparginase 5000 IU/m2 for 14 consecutive days
plus prednisolone 1 mg/kg/day for 28 days]. Patients with +ve Phila-
delphia, additionally received Imatinib 400 mg/day, and were followed
up by PCR for the expression of p210 fusion protein (BCR/Abl) to shift
them to another treatment protocol (Hypper- CVAD protocol) [12]. For-
tunately, Philadelphia +ve patients in this study did not express p210
fusion protein. All involved patients have showngood response to treat-
ment proved by negligible bone marrow and peripheral blast cells. All
patients were subjected to detailed history taking and medical exami-
nation concerning their disease. An informed consent was obtained
from all included subjects.
Sample collection
Blood samples (5 to 10 ml) were drawn from all subjects into tubes
without anticoagulant before any therapeutic measures were started
and after 4 weeks of induction therapy. Serum samples were separated
then stored at−80°C until subsequent processing and measurements.
Assay procedures
Survivin concentration was measured using enzyme-linked immu-
nosorbent assay (ELISA) kit from Quantikine® Human Survivin Immu-
noassay (R&D Systems, Inc., Minneapolis, USA).
TNF-α concentration was measured using enzyme-linked immuno-
sorbent assay (ELISA) kit from Quantikine® Human Tumor Necrosis
Factor-α (hTNF- α) Immunoassay (R&D Systems, Oxon, UK).
The assay employs the quantitative sandwich enzyme immunoas-
say technique. The steps of both kits were those described by the
manufacturer.
Statistical analysis
Data were analyzed using SPSS 15 software. Quantitative variables
were reported as mean±SD. Student's t test was performed to assess
whether the results are signiﬁcant or not. The level of signiﬁcance was
set at Pb0.05. The associations between studied parameters and clinico-
pathological parameters were assessed byχ2 test. The best cutoff value
that maximizes sensitivity and speciﬁcity and differentiates acute
lymphoblastic patients from controls was calculated by using the ROC
(receiver operating characteristic) curve.
Results
Themean serumsurvivin levelwas signiﬁcantly higher in acute lym-
phoblastic patients (28.00±11.23 pg/mL; range 11.6–63.6 pg/mL) than
in the control group (9.05±3.02 pg/mL; range 3.31–14.77 pg/mL),
P=0.00. A signiﬁcant reduction of survivin level was observed in ALL
patients after therapy (mean 20.7±5.6 pg/mL; range 11.6–30.5 pg/
mL) than in ALL patients before therapy (mean 35.28±10.71 pg/mL;
range 20.5–63.6 pg/mL), as shown in Fig. 1. TNF-αwas also signiﬁcantly
higher in acute lymphoblastic patients (mean 231.98±116.5 pg/mL;
range 50.0–476.4 pg/mL) than in the control group (mean 51.9±
41.25 pg/mL; range 20.53–190.74 pg/mL), P=0.00. TNF-α showedsigniﬁcant lower levels in ALL patients after therapy (mean 180.84±
98 pg/mL; range 44.47–384.47 pg/mL) than before therapy (mean
275.13±108.3 pg/mL; range 50.0–476.4 pg/mL) as shown in Fig. 2.
Serum survivin showed a higher signiﬁcant reduction in its level after
therapy than TNF-α; (Pb0.01) and (Pb0.05) respectively. The best
cut-off values for investigated parameters were calculated by the ROC
curve as 15.18 pg/mL for survivin and 60.05 pg/mL for TNF-α (Fig. 3).
On the contrary to TNF-α, the percentage of patients with survivin con-
centrations above the cutoff value was signiﬁcantly higher in ALL pa-
tients before therapy than after therapy(Pb0.05), while no signiﬁcant
reduction was found with TNF-α. (Figs. 4 and 5). Moreover, survivin
showed a positive signiﬁcant correlation with TNF-α (Pb0.05), bone
marrow blast cells (Pb0.01) and blast cell count in peripheral blood
(Pb0.05), but TNF-αwas only correlatedwith blast cell count in periph-
eral blood (Pb0.05). As regards Philadelphia chromosome, it was posi-
tively correlated to both peripheral and bone marrow blast cells,
Furthermore correlated to survivin (Pb0.01) and TNF-α (Pb0.05).Discussion
Acute leukemia is the 4th most common cancer among males and
the 3rd most common cancer among females [13].
Impaired apoptosis is mediated by members of the inhibitor of
apoptosis proteins (IAP) family such as survivin. Survivinwas described
in a number of different tumors and found to correlate with poor
prognosis in a variety of cancers including hematologic malignancies
Fig. 3. Receiver operating characteristic (ROC) curves for serum survivin and TNF-α to
discriminate between ALL pateints and normal control group. The arrows denote best
cut-off pointsof survivin at 15.18 pg/mL (sensitivity=91.7%, speciﬁcity=100%, area
under the curve (AUC)=0.985, Pb0.01) and TNF-α at 60.05 pg/mL(sensitivi-
ty=90.0%, speciﬁcity=80%, AUC=0.94, Pb0.01).
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agents, caspase 3, 7, and 9, or Fas ligand-induced stimuli [15]. The role of
TNF-α in ALL is very complex. The endogenous production of TNF-α in
ALL blasts is connected with their resistance to chemotherapy. More-
over, a high serum level of TNF-α can be a predictor of early disease re-
lapse [4]. It was proved that stimulation of venous smooth muscle cells
in human with Angiotensin II and TNF-α led to a rapid up regulation of
transcription factor, Kruppel-like factor 5, that increase survivin expres-
sion [16].
In the present study; survivin and TNF-α levels were estimated in
the circulation of adult patients with newly diagnosed untreated ALL
and after initial treatment in order to ﬁnd out their implication in the
pathogenesis of ALL and to evaluate their prognostic value. We used aFig. 4. The percentage of patients with serum survivin abmethodologically simple ELISA that can be applied to large clinical stud-
ies. The results demonstrated signiﬁcantly increased levels of survivin
and TNF-α in acute lymphoblastic patients compared to normal control
group, suggesting that both survivin and TNF-α have relevant biological
activity in ALL patients. Altieri [17] reported that survivin overexpres-
sion has been identiﬁed as a negative prognostic factor in various cancer
types and was implicated in resistance to apoptosis induction by anti-
cancer agents. Also, Drabko et al. [18] found that serum TNF-α level
was increased in children with ALL compared to control group. Our
results are supported by other authors, but so far; the prognostic
value of these two biochemical markers in adult leukemic patients
was not previously elucidated. In the present study a signiﬁcant reduc-
tion in both survivin (P=0.00) and TNF-α (Pb0.05) in acute lympho-
blastic patients was clearly detected in response to the treatment. On
contrary to TNF-α that showed no signiﬁcant difference in its positivity
rate in response to therapy, survivin had a signiﬁcant higher positivity
rate in acute lymphoblastic patients before therapy (100%) in compari-
son to that after therapy (83.33%). Esh et al. [14] published that pediat-
ric ALL patients who were suffering relapse of the disease had a
signiﬁcant higher basal level of survivin detected by ﬂow cytometry
than patients still in remission. Although survivin and TNF-α protein
in this study were reduced in response to therapy, their levels were
still higher than in the control group. This may probably be due to
short follow-up period (4 weeks) of the patients or it may be due to
the lysis of circulating tumor cells and the release of their intracellular
survivin or it could indicate the persistence of residual tumor cells.
This may explain the ﬁnding of Guney et al. [19] that serum survivin
levels did not change signiﬁcantly after chemotherapy in patients
with breast cancer. Moreover, Potapnev et al. [20] detected higher
plasma levels of TNF-α in childhood ALL compared to healthy children
that showed no signiﬁcant association with treatment response.
Patients with acute- or lymphoma-type adult T-cell leukemia (ATL)
have a poor outcome because of the intrinsic drug resistance to chemo-
therapy. Protection from apoptosis is a common feature involved in
multidrug-resistance of ATL [21]. However, we couldn't ﬁnd any signif-
icant correlation between themicroscopic types of ALL with survivin or
TNF-α.
The observation that inhibition of survivin interactions by antisense
or dominant-negative approaches in different transformed cell modelsove the cutoff value in the different studied groups.
Fig. 5. The percentage of patients with serum TNF-α above the cutoff value in the different studied groups.
115M.B. Ahmed et al. / Clinical Biochemistry 45 (2012) 112–116can induce apoptosis of malignant cells led to the assumption that
targeting of survivin could represent a novel strategy to treat cancer
patients [9]. In the current study, survivin showed a positive signiﬁcant
correlation with both bone marrow blast cells and blast cell count in
peripheral blood, while TNF-α was only correlated with peripheral
blast cells. This was agreed with Potapnev et al. [20] who demonstrated
a positive correlation between blast cell count in peripheral blood and
TNF-α. However, Esh et al. [14] reported no association of survivin
levels with established risk factors.
Malcles et al. [5] showed that survivin-ΔEx3, one of the spliced
variants, is a central regulator at the mitochondrial checkpoint during
TNF-α induced apoptosis, where it binds to Bcl-2 and to activated
caspase-3, acting as an adaptor, which allows Bcl-2 to inhibit the activ-
ity of caspase-3. This may explain the positive correlation between
survivin and TNF-α detected in the present study and demonstrate
the antiapoptotic effects of survivin through opposing the apoptotic
effect of TNF-α and survival of malignant cells.
The characteristic large change in the chromosomes of cancer cells is
an important predictor of outcome. Some cytogenetic subtypes have a
worse prognosis than others [21]. Paietta et. al. [22] reported that a
translocation between chromosomes 9 and 22, known as the Philadel-
phia chromosome, occurs in about 20% of adult cases of ALL. In this
study 16.6% of our ALL patients has Philadelphia chromosome. They
were positively correlated to both peripheral and bone marrow blast
cells that was agreed with their bad prognostic factor in ALL patients.
Moreover, our positive Philadelphia chromosome patients showed a
higher signiﬁcant positive correlation with survivin (Pb0.01) than
with TNF-α (Pb0.05).
These results indicated that serum survivin and TNF-α levels are
increased in patients having ALL and they correlatedwith known estab-
lished risk factors in ALL as peripheral blast cells and Philadelphia chro-
mosome. However, survivin showed more signiﬁcant correlation with
bonemarrow blast cells and other prognostic criteria in ALL, suggesting
that survivin may enhance the aggressive behavior of this tumor. As
compared with TNF-α, survivin had a better sensitivity and speciﬁcity
cut off value that showed a signiﬁcant lower positivity rate in ALL
patients in response to the therapy. We conclude that the survivin
serum level correlates with the extent of disease and associated with
aggressive clinical behavior, highlighting the usefulness of survivin as
a potential diagnostic and a novel prognostic factor for survival in ALL.
Future studies should focus on the prospective analysis of these assays
against long followup treatment in largermulticentric studies for better
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